Publications by authors named "K Grimwood"
Pseudomonas aeruginosa bloodstream infections in children in Queensland, Australia, 2000-2019.
J Paediatr Child Health
December 2024
Aim: To investigate the incidence, risk factors and outcomes of Pseudomonas aeruginosa bloodstream infections (P-BSI) in Queensland children aged 0-18 years.
Methods: A retrospective data-linkage study was conducted of P-BSI identified by Pathology Queensland laboratories from resident Queensland children admitted to publicly-funded Queensland Hospitals between 2000 and 2019. We estimated age-standardised incidence of P-BSI and case fatality ratios (48 h, 7-, 30- and 90-day all-cause mortality from the date of the blood culture collection).
(Group A , GAS) is a human-restricted pathogen that causes a wide range of diseases from pharyngitis and scarlet fever to more severe, invasive infections such as necrotising fasciitis and streptococcal toxic shock syndrome. There has been a global increase in both scarlet fever and invasive infections during the COVID-19 post-pandemic period. The aim of this study was the molecular characterisation of 17 invasive and non-invasive clinical non-1 GAS isolates from an Australian tertiary hospital collected between 2021 and 2022.
View Article and Find Full Text PDFParenteral aciclovir for suspected herpes simplex virus infection in children: 0-18 years.
J Antimicrob Chemother
November 2024
Article Synopsis
- A study reviewed medical records from eight hospitals in Australia and New Zealand examining how intravenous aciclovir is prescribed for suspected herpes simplex virus (HSV) disease in neonates and older children between January and December 2019.
- Out of 1,426 patients, most received aciclovir for suspected cases without definitive HSV testing; notably, only a small fraction had confirmed diagnoses among older children, indicating potentially excessive and unjustified prescribing.
- Among the patients, adverse effects included instances of nephrotoxicity and extravasation injuries, raising concerns about the safety and necessity of such treatments in the pediatric population.
Article Synopsis
- * Both bacteria often coexist but can either cooperate or compete depending on environmental conditions, complicating their impact on disease severity and treatment outcomes.
- * There is a push for developing vaccines targeting these bacteria to reduce respiratory diseases among young children, highlighting the need for more research on their interactions and effective prevention strategies.
Background: Pediatric community-acquired pneumonia (CAP) can lead to long-term respiratory sequelae, including bronchiectasis. We determined if an extended (13-14 days) versus standard (5-6 days) antibiotic course improves long-term outcomes in children hospitalized with CAP from populations at high risk of chronic respiratory disease.
Methods: We undertook a multicenter, double-blind, superiority, randomized controlled trial involving 7 Australian, New Zealand, and Malaysian hospitals.